"rationale","versionIdentifier","uuid:ID","instanceType","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","66707a42-573b-4a63-9202-a7c8e81e2fb2","StudyVersion","StudyVersion_1"
